- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT03009253
Translational Research on Locally Advanced Pancreatic Adenocarcinoma (TRLAPA)
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
The trial is prepared to be registered on the clinicaltrail.gov. Quality assurance plan: Every participant is enrolled or excluded by two practiced investigators. And two investigators participated in all steps of the trail, including the record of the data, and the investigators will compare the data. If the data is consistent,the investigators would record the data; if not, the data would be checked and decided by the two investigators. All the steps and data are site monitored and audited by the workers of research and financial department of National Cancer Center/ Cancer Hospital, Chinese Academy of Medical Sciences.
Data check: The investigators compare data entered into the registry against predefined rules for range or consistency with other data fields in the registry.Source data verification to assess the accuracy, completeness, or representativeness of registry data by comparing the data to external data sources, including medical records and electronic case report forms.
Data dictionary that contains detailed descriptions of each variable used by the registry,including the source of the variable, coding information, and normal ranges if relevant.Standard Operating Procedures to address registry operations and analysis activities,such as participants recruitment, data collection, data management, data analysis,reporting for adverse events, and change management. All registry operations would be done according to specific steps, and by two practiced investigators.
Sample size assessment to specify the number of participants or participant years necessary to demonstrate an effect. According to the formula to differ advantages and disadvantages, the investigators need at least 80 participants to take part in the trail.
The investigators can recruit about 20 participants every year according to previous experiences, so the investigators should recruit at least for two years.
Plan for missing data: the investigators would collect as much data as possible, and the investigators exclude the participants who cannot cooperate on recruitment. And the investigators manage situations according to statistical principles where variables are reported as missing, unavailable, "non-reported," uninterpretable, or considered missing because of data inconsistency or out-of-range results.
Statistical analysis plan: Kaplan-Meier method would be used to analyze the difference of survival time between the two groups, and the local control rate of the two groups would be compared by chi square test. Statistical analyses would be performed by using IBM SPSS Statistics(version 20; IBM, Chicago, USA). The level of significance is defined as P < 0.05.
Type d'étude
Inscription (Anticipé)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Beijing
-
Beijing, Beijing, Chine, 10021
- Recrutement
- Cancer Institute and Hospital ,China Academy of Medical Sciences
-
Contact:
- Xu Che, M.D.
- Numéro de téléphone: 8610-87787120
- E-mail: xu.che@hotmail.com
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- have cytologic or pathological proof of pancreatic adenocarcinoma without surgery contraindication score of ECOG is between 0 and 1 evaluation of CT is unresectable
Exclusion Criteria:
- metastatic pancreatc adenocarcinoma malignant tumors history allergic to 5-FU have difficulty in swallowing joined other clinical trails cardiac and renal disease active infection
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Concurrent chemoradiotherapy(CCRT) Group
Concurrent chemoradiotherapy (Total dose: 30-40 Gy; Single dose: 3-4 Gy; Frequency: 10; S-1 orally (80 mg/m2/d),2 weeks) Followed by chemotherapy: Gemcitabine(GEM), 1000 mg/m2 ,Day 1,8 ); taking S-1 orally (80 mg/m2/d, bid on Day 1-14, Q21d, 3 cycles)
|
the 2 arms have different orders of treatment,participants in arm A accept concurrent chemoradiotherapy at first and then accept evalution for surgery.In arm B,participants accept concurrent chemoradiotherapy at first and then accept evalution for surgery.
|
|
Expérimental: Chemotherapy Group
Chemotherapy (Gemcitabine(GEM), 1000 mg/m2 ,Day 1,8 ); taking S-1 orally (80 mg/m2/d, bid on Day 1-14, Q21d, 3 cycles) Followed by Concurrent chemoradiotherapy: (Total dose: 30-40 Gy; Single dose: 3-4 Gy; Frequency: 10; S-1 orally (80 mg/m2/d),2 weeks) |
the 2 arms have different orders of treatment,participants in arm A accept concurrent chemoradiotherapy at first and then accept evalution for surgery.In arm B,participants accept concurrent chemoradiotherapy at first and then accept evalution for surgery.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
translational resection rate
Délai: half a year
|
half a year
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Taux de contrôle local
Délai: 2 années
|
LCR
|
2 années
|
|
progression-free survival
Délai: 2 years
|
PFS
|
2 years
|
Collaborateurs et enquêteurs
Les enquêteurs
- Chercheur principal: Chengfeng Wang, B.A., Investigator CancerIHCAMS
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Anticipé)
Achèvement de l'étude (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- GHGI061
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur order of treatment
-
Memorial Sloan Kettering Cancer CenterRésiliéLes familles ou proches parents des patients traités au MSKCC pour des carcinomes épidermoïdes non cutanés du | Voies aérodigestives supérieuresÉtats-Unis
-
Columbia UniversityNeurolutions, Inc.RetiréAccident vasculaire cérébral | Hémiparésie
-
Covenant HealthAlberta Innovates Health SolutionsInconnueMoignon d'amputation | Jambe d'oedème | Cicatrisation retardée | Maladie vasculaire périphérique avec complications
-
Hospital Clinic of BarcelonaInconnue
-
University of MichiganWallace H Coulter Center for Translational ResearchComplété
-
Dana-Farber Cancer InstituteBreast Cancer Research FoundationPas encore de recrutementCancer du sein | Carcinome du sein | Cancer du sein ER positif | Cancer du sein - Femme | Cancer du sein PR-positifÉtats-Unis
-
Emory UniversityNational Heart, Lung, and Blood Institute (NHLBI)Complété
-
Western Carolina UniversityRecrutementAccident vasculaire cérébralÉtats-Unis
-
Morehouse School of MedicineNational Institute on Minority Health and Health Disparities (NIMHD)RecrutementDiabète | Diabète de type 2 | Maladie chronique | Comportement sédentaire | Mode de vie sain | Nutrition, Santé | Famille | Recherche familiale | Famille et MénageÉtats-Unis
-
University Health Network, TorontoAnemia Institute for Research & EducationComplétéCardiopathie | CoagulopathieCanada